Causes, clinical findings and therapeutic options in chylomicronemia syndrome, a special form of hypertriglyceridemia
Open Access
- 10 February 2022
- journal article
- review article
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 21 (1) , 1-14
Abstract
The prevalence of hypertriglyceridemia has been increasing worldwide. Attention is drawn to the fact that the frequency of a special hypertriglyceridemia entity, named chylomicronemia syndrome, is variable among its different forms. The monogenic form, termed familial chylomicronemia syndrome, is rare, occuring in 1 in every 1 million persons. On the other hand, the prevalence of the polygenic form of chylomicronemia syndrome is around 1:600. On the basis of the genetical alterations, other factors, such as obesity, alcohol consumption, uncontrolled diabetes mellitus and certain drugs may significantly contribute to the development of the multifactorial form. In this review, we aimed to highlight the recent findings about the clinical and laboratory features, differential diagnosis, as well as the epidemiology of the monogenic and polygenic forms of chylomicronemias. Regarding the therapy, differentiation between the two types of the chylomicronemia syndrome is essential, as well. Thus, proper treatment options of chylomicronemia and hypertriglyceridemia will be also summarized, emphasizing the newest therapeutic approaches, as novel agents may offer solution for the effective treatment of these conditions.Keywords
Funding Information
- Hungarian Scientific Research Fund (GINOP-2.3.2-15-2016-00005)
- University of Debrecen
This publication has 151 references indexed in Scilit:
- HypertriglyceridemiaNutrients, 2013
- Atypical angiopoietin-like protein that regulates ANGPTL3Proceedings of the National Academy of Sciences, 2012
- Lipase maturation factor 1: A lipase chaperone involved in lipid metabolismBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2012
- Mutations in lipoprotein lipase that block binding to the endothelial cell transporter GPIHBP1Proceedings of the National Academy of Sciences, 2011
- Management of Hypertriglyceridemia in the Diabetic PatientCurrent Diabetes Reports, 2010
- A Highly Conserved Motif within the NH2-terminal Coiled-coil Domain of Angiopoietin-like Protein 4 Confers Its Inhibitory Effects on Lipoprotein Lipase by Disrupting the Enzyme DimerizationJournal of Biological Chemistry, 2009
- Identification of a New Functional Domain in Angiopoietin-like 3 (ANGPTL3) and Angiopoietin-like 4 (ANGPTL4) Involved in Binding and Inhibition of Lipoprotein Lipase (LPL)Journal of Biological Chemistry, 2009
- The Angiopoietin-like Proteins ANGPTL3 and ANGPTL4 Inhibit Lipoprotein Lipase Activity through Distinct MechanismsJournal of Biological Chemistry, 2009
- Gender-Related Differences in Electrocardiographic Parameters and Their Association With Cardiac Events in Patients After Myocardial InfarctionThe American Journal of Cardiology, 2008
- Ligand-activated PPARβ efficiently represses the induction of LXR-dependent promoter activity through competition with RXRMolecular and Cellular Endocrinology, 2006